氟维司群联合哌柏西利对比来曲唑联合哌柏西利一线治疗内分泌敏感HR阳性/HER2阴性晚期乳腺癌的随机临床试验
该国际随机开放标签2期研究纳入486例内分泌敏感、HR阳性/HER2阴性晚期乳腺癌患者,一线随机接受氟维司群联合哌柏西利或来曲唑联合哌柏西利。
要点
- 氟维司群联合哌柏西利一线治疗的PFS未优于来曲唑联合哌柏西利。
- 两组客观缓解率和3年总生存率无显著差异。
- 两方案3-4级不良事件相当,未发现新安全性信号。
核心结论
- 在 endocrine-sensitive、HR阳性/ERBB2阴性晚期乳腺癌一线治疗中,氟维司群联合哌柏西利虽显示抗肿瘤活性,但未较来曲唑联合哌柏西利改善PFS。
研究设计与样本
- 国际、随机、开放标签、2期临床研究,2015年7月30日至2018年1月8日从7国47个中心入组486例患者,按1:1随机分配至氟维司群-哌柏西利组(243例)或来曲唑-哌柏西利组(243例)。
- 分层因素为疾病表现类型(新发 vs 复发)和内脏受累(有 vs 无)。
主要发现
- 两组客观缓解率分别为46.5%和50.2%,3年总生存率分别为79.4%和77.1%,均无显著差异。
- 3-4级不良事件在治疗组间相当,未发现新安全性信号,无治疗相关死亡报告。
关键数值与推荐
- 主要终点为研究者根据RECIST 1.1评估的PFS。
- 分层因素包括疾病表现类型(新发 vs 复发)和内脏受累(有 vs 无)。
临床怎么用
- 对于内分泌敏感、HR阳性/ERBB2阴性晚期乳腺癌的一线治疗,来曲唑联合哌柏西利仍为标准选择,氟维司群联合哌柏西利未显示PFS优势。
局限性
- 本研究为2期、开放标签研究,样本以白人女性为主(94.9%),其他种族代表性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The cyclin-dependent kinase 4 and 6 inhibitor palbociclib in combination with letrozole has become a standard first-line treatment for patients with endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer. Meanwhile, the antiestrogen fulvestrant was shown to be superior to anastrozole in the absence of cyclin-dependent kinase 4 and 6 inhibition for this patient population. OBJECTIVE: To assess whether fulvestrant is superior to letrozole when combined with palbociclib in the first-line scenario. DESIGN, SETTING, AND PARTICIPANTS: In this international, randomized, open-label, phase 2 clinical study conducted from July 30, 2015, to January 8, 2018, patients with hormone receptor-positive, ERBB2-negative advanced breast cancer with no prior therapy in the metastatic setting and endocrine-sensitive criteria were recruited from 47 centers in 7 countries. Data were analyzed from February 11 to May 15, 2020. INTERVENTIONS: Patients were randomly assigned (1:1 ratio) to receive palbociclib with either fulvestrant or letrozole. Stratification factors were type of disease presentation (de novo vs recurrent) and the presence of visceral involvement (yes vs no). MAIN OUTCOMES AND MEASURES: The primary end point was investigator-assessed progression-free survival determined by Response Evaluation Criteria in Solid Tumors, version 1.1. RESULTS: A total of 486 women (median age, 63 years [range, 25-90 years]; 3 Asian women [0.6%]; 4 Black women [0.8%]; 461 White women [94.9%]; 18 women of unknown race [3.7%]) were randomized (243 to fulvestrant-palbociclib and 243 to letrozole-palbociclib). Median investigator-assessed progression-free survival was 27.9 months (95% CI, 24.2-33.1 months) in the fulvestrant-palbociclib group vs 32.8 months (95% CI, 25.8-35.9 months) in the letrozole-palbociclib group (hazard ratio, 1.13; 95% CI, 0.89-1.45; P = .32). This result was consistent across the stratification factors. No significant differences were observed in objective response rate (46.5% vs 50.2%) and 3-year overall survival rate (79.4% vs 77.1%) for fulvestrant-palbociclib and letrozole-palbociclib, respectively. Grade 3-4 adverse events were comparable among treatment groups, and no new safety signals were identified. No treatment-related deaths were reported. CONCLUSIONS AND RELEVANCE: Although fulvestrant-palbociclib demonstrated significant antitumor activity, this randomized clinical trial failed to identify an improvement in progression-free survival with this regimen over letrozole-palbociclib in patients with endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02491983.
引用
- Llombart-Cussac A, Pérez-García JM, Bellet M, et al. Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 34617955. doi:10.1001/jamaoncol.2021.4301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。